已收录 268920 条政策
 政策提纲
  • 暂无提纲
Tenidap sodium inhibits secretory non-pancreatic phospholipase A2synthesis by foetal rat calvarial osteoblasts
[摘要] Tenidap (TD) was initially defined as a dual inhibitor of cyclooxygenase and lipoxygenase. This study was designed to assess its inhibitory activity against proinflammatory phospholipase A2. This study shows that TD inhibits the synthesis of pro-inflammatory secretory non-pancreatic phospholipase A2(sPLA2). Concentrations as low as 0.25 μg/ml (0.725 μM) reduced the release of sPLA2by 40% from foetal rat calvarial osteoblasts stimulated with IL-1β and TNFα, whereas a concentration of 2.5 μg/ml (7.25 μM) reduced the release by over 80%. TD also markedly reduced the release of sPLA2from unstimulated cells. There was no direct inhibition of sPLA2enzymatic activity by TDin vitro. Northern blot analysis showed that TD did not affect the sPLA2mRNA levels; however, immunoblotting showed a dose-dependent reduction in sPLA2enzyme. These results, together with a marked reduction in sPLA2enzymatic activity, suggest that TD inhibits sPLA2synthesis at the post-transcriptional level. Therefore TD seems to inhibit the arachidonic acid cascade proximally to cyclooxygenase and lipoxygenase and its anti-inflammatory activity may be related at least in part to the inhibition of sPLA2synthesis.
[发布日期]  [发布机构] 
[效力级别]  [学科分类] 生理学与病理学
[关键词]  [时效性] 
   浏览次数:2      统一登录查看全文      激活码登录查看全文